Fisher & Paykel (ASX: FPH) Raises Revenue and Profit Forecast – Here’s Why

Sonal Goyal

23 February 2026 01:11 PM AEDT

Fisher & Paykel (ASX: FPH) Raises Revenue and Profit Forecast – Here’s Why

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Fisher & Paykel Healthcare shares rose 5.09% to AUD 33.27 on 23 February 2026.
FY26 operating revenue guidance has been upgraded to approximately NZD 2.30 billion.
Net profit after tax is now expected to be between NZD 450 million and NZD 470 million.

Fisher & Paykel Healthcare Corporation Limited (ASX:FPH) has upgraded its revenue and earnings guidance for the financial year ending 31 March 2026, citing favourable exchange rates and continued growth across its hospital product portfolio. Shares in the company rose 5.09% to AUD 33.27 during morning trade on 23 February 2026, taking year-to-date gains to 2.78%.

FY26 Revenue and Profit Guidance Raised

The company had previously guided, on 29 November 2025 and based on a NZD:USD exchange rate of 0.57, for:

Operating revenue: NZD 2.17 billion to NZD 2.27 billion
Net profit after tax (NPAT): NZD 410 million to NZD 460 million

At 31 January 2026 exchange rates (NZD:USD 0.60), Fisher & Paykel Healthcare now expects:

Operating revenue: Approximately NZD 2.30 billion
NPAT: Approximately NZD 450 million to NZD 470 million

The updated guidance does not incorporate any potential refund of US tariffs paid during FY26.

Tariff Developments Under Review

The company noted that the United States Supreme Court invalidated tariffs imposed under the International Emergency Economic Powers Act (IEEPA).

Management stated there remain uncertainties regarding the implications of the ruling, including refund processes and the application of free trade agreements and the Nairobi Protocol. An update on tariff impacts is expected with the full-year results at the end of May.

Current and proposed tariff structures are being assessed in the context of cost increases and operational initiatives.

Operational Update

The company reported continued growth across its hospital product range during the second half of FY26 to date.

Relative seasonal respiratory hospitalisations in the Northern Hemisphere winter may influence second-half performance. Continuous improvement initiatives and efficiency gains have contributed to gross margin and operating margin improvements.

Fisher & Paykel Healthcare designs, manufactures and markets products used in acute and chronic respiratory care, surgery and obstructive sleep apnea treatment, with distribution in more than 120 countries.

Key Financial Metrics (Updated FY26 Guidance)

Operating revenue: ~NZD 2.30 billion
Net profit after tax: NZD 450–470 million
Previous revenue guidance: NZD 2.17–2.27 billion
Previous NPAT guidance: NZD 410–460 million

Fisher & Paykel Healthcare has revised its FY26 financial outlook upward, supported by exchange rate movements and hospital product sales trends. The market response saw the stock move higher in morning trade, as investors assessed the updated revenue and earnings expectations ahead of full-year results in May.

Frequently Asked Questions (F&Q)

What is Fisher & Paykel Healthcare’s updated FY26 revenue guidance?
The company now expects operating revenue of approximately NZD 2.30 billion for FY26.
What is the revised net profit after tax forecast?
NPAT is expected to be in the range of NZD 450 million to NZD 470 million.
How did the share price react to the announcement?
Shares rose 5.09% to AUD 33.27 during morning trading on 23 February 2026, taking year-to-date gains to 2.78%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.